Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma

AIDS

Volumn 19, Issue 16, 2005, Pages 1915-1916

  Vaccher, Emanuela ^a   Di Gennaro, Giampiero ^a   Simonelli, Cecilia ^a   Schioppa, Ornella ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LEUKOPENIA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; REMISSION; THROMBOCYTOPENIA;

EID: 27544497964     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000189855.06194.ce     Document Type: Article

References (12)

1. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13:2105-2111.
2. Tavio M, Nasti G, Spina M, Errante D, Vaccher E, Tirelli U. Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma. Ann Oncol 1998; 9:923.
3. Cattelan AM, Calabro ML, Aversa SM, Zanchetta M, Meneghetti F, De Rossi A, et al. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 1999; 35:1809-1815.
4. Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001; 15:629-633.
5. Nasti G, Martellotta F, Berretta M, Mena M, Fasan M, Di Perri G, et al. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2003; 98:2440-2446.
6. Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer 2001; 37:1288-1295.
7. Gates AE, Kaplan LD. AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (Huntingt) 2002; 16:657-665.
8. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997; 8:837-855.
9. O'Leary JJ, Shapiro RL, Ren CJ, Chung N, Cohen HW, Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 1999; 5:181-187.
10. Ensoli B, Sturzi M, Monini P. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv Cancer Res 2001; 81:161-200.
11. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27:23-44.
12. Kobayashi K, Takeda Y, Akiyama Y, Soma T, Handa T, Kudo K, Kudoh S. Reduced irinotecan-induced side-effects by the oral alkalization [Abstract]. Proc Am Soc Clin Oncol 1999; 18:1900.